{"corpus_id":35107128,"paper_sha":"de0e7340ba8e319e3fc12c79079b52e0f7ebb92e","doi":"10.1542/peds.45.3.444","arxiv_id":null,"pmid":5442915,"pmcid":null,"mag_id":2130169587,"dblp_id":null,"acl_id":null,"title":"Trivalent oral poliovirus vaccine: a comparison of two infant immunization schedules.","year":1970,"publication_date":"1970-03-01","venue":"Pediatrics","journal":{"name":"Pediatrics","pages":"\n          444-8\n        ","volume":"45 3"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","Study"],"pubmed_pub_types":["Comparative Study","Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":0,"citation_count":16,"influential_citation_count":0,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Antibodies","mj":false,"qs":[{"q":"analysis","mj":false,"ui":"Q000032"}],"ui":"D000906"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Immunization Schedule","mj":true,"ui":"D007115"},{"d":"Infant","mj":false,"ui":"D007223"},{"d":"Poliomyelitis","mj":false,"qs":[{"q":"prevention & control","mj":true,"ui":"Q000517"}],"ui":"D011051"},{"d":"Poliovirus Vaccine, Oral","mj":true,"ui":"D011055"}],"chemicals":[{"n":"Antibodies","ui":"D000906","reg":"0"},{"n":"Poliovirus Vaccine, Oral","ui":"D011055","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"The Public Health Service Advisory Committee on Immunization Practices (ACIP) and the Committee on Infectious Diseases of the American Academy of Pediatrics have not reached complete agreement in their currently recommended schedules for primary infant immunization with trivalent oral poliovirus vaccine (OPV).\n To determine which if either of these is the more efficacious, 200 infants were immunized with trivalent OPV. Approximately 50% of these infants completed the 3 dose primary series recommended by the ACIP; remaining infants completed the 4 dose series recommended by the Academy. Microneutralization titers to all three poliovirus types were determined at appropriate time intervals.\n At the completion of the study, a satisfactory percentage of individuals in both groups exhibited microneutralization titers of 1:10 or greater to all three poliovirus types. During the course of study, minor differences were noted between the two groups in the percentage of individuals with titers against poliovirus types 1 and 3.","claims":[{"public_id":"cl_147c359af5fe0da764cf189c929713f8","status":"active","text":"Both the 3-dose and 4-dose primary infant immunization schedules produced a satisfactory percentage of infants with microneutralization titers of 1:10 or greater to all three poliovirus types.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_147c359af5fe0da764cf189c929713f8"},{"public_id":"cl_3b9b4df8adb770c085798c875aca9877","status":"active","text":"Minor differences were observed between the two schedules in the percentage of individuals with titers against poliovirus types 1 and 3 during the study.","confidence":0.86,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_3b9b4df8adb770c085798c875aca9877"},{"public_id":"cl_0097f69df8d5233f676d43a8e0661b25","status":"active","text":"The comparative immunogenicity assessment did not show a clear efficacy advantage for either infant immunization schedule.","confidence":0.74,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_0097f69df8d5233f676d43a8e0661b25"}],"concepts":[{"public_id":"co_06a306cdb9a10816cb72442d017b5e49","status":"active","name":"primary infant immunization","description":"The initial vaccination series given to infants to induce protective immunity.","types":["intervention"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_06a306cdb9a10816cb72442d017b5e49"},{"public_id":"co_41a1d8d8fa54ea71302cfb077e9aedfe","status":"active","name":"poliovirus types 1 and 3","description":"Two poliovirus serotypes evaluated for antibody response in the immunization comparison.","types":["viral serotypes"],"aliases":["types 1 and 3"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_41a1d8d8fa54ea71302cfb077e9aedfe"},{"public_id":"co_47252b8bdc22854a698aeafc4deab232","status":"active","name":"infant immunization schedules","description":"Primary vaccination schedules used to immunize infants in the comparative study.","types":["intervention"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_47252b8bdc22854a698aeafc4deab232"},{"public_id":"co_663979e5c3081705cff685d97363236e","status":"active","name":"microneutralization titers","description":"Measured antibody neutralization levels used to assess immune response to poliovirus.","types":["measurement"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_663979e5c3081705cff685d97363236e"},{"public_id":"co_6f7ed0ee2b0492893e16f4fd4f749b39","status":"active","name":"three poliovirus types","description":"The three poliovirus serotypes included in the trivalent vaccine and serologic testing.","types":["viral serotypes"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6f7ed0ee2b0492893e16f4fd4f749b39"},{"public_id":"co_7094bf420015b62a6a306445c9870a72","status":"active","name":"immune response","description":"The antibody response measured after vaccination.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7094bf420015b62a6a306445c9870a72"},{"public_id":"co_7b88dd351a4f276ed9b9f7475d242403","status":"active","name":"3-dose primary series","description":"An infant immunization schedule consisting of three primary doses.","types":["immunization schedule"],"aliases":["ACIP schedule"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7b88dd351a4f276ed9b9f7475d242403"},{"public_id":"co_88e5cb61983a46e8a922039a75b27b64","status":"active","name":"4-dose series","description":"An infant immunization schedule consisting of four primary doses.","types":["immunization schedule"],"aliases":["Academy schedule"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_88e5cb61983a46e8a922039a75b27b64"},{"public_id":"co_d81a10719295a0d4830c22def42aa29d","status":"active","name":"trivalent oral poliovirus vaccine","description":"An oral poliovirus vaccine formulation that targets all three poliovirus serotypes.","types":["vaccine"],"aliases":["OPV"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d81a10719295a0d4830c22def42aa29d"}],"external_ids":{"DOI":"10.1542/peds.45.3.444","ArXiv":null,"PubMed":5442915,"PubMedCentral":null,"MAG":2130169587,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/35107128","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"unknown","references_indexed":false,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":634852,"paper_uid":"4625e48c-1dbe-42c9-b6d9-bf7939d01734","canonical_identity":{"paper_id":634852,"paper_uid":"4625e48c-1dbe-42c9-b6d9-bf7939d01734","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/35107128"}